Countdown to 2021 CBIIC:

LI Yishi

Principle of HaoYue Capital

l  Yishi joined Haoyue Capital in Jan 2017. He has more than 15-year experience in R&D, marketing, entrepreneurship and investment

l  Prior to this, Yishi was the strategy and market-entry director of 3D Medicine, a precision medicine venture. He covered the R&D, marketing, entry plan and registration of gene sequencing.He also raised more than 100 million RMB for 3D Medicine. Prior to 3D Medicine, Yishi operated the anti-tumor immunotherapy strategy at Bristol-Myers Squibb and lead R&D at Qianhong Bio-pharma

l  Yishi holds a Ph.D degree in Molecular Biology from University of South California and a M.B.A Degree with Honor from CEIBS